Identification of a PA-Binding Peptide with Inhibitory Activity against Influenza A and B Virus Replication

There is an urgent need for new drugs against influenza type A and B viruses due to incomplete protection by vaccines and the emergence of resistance to current antivirals. The influenza virus polymerase complex, consisting of the PB1, PB2 and PA subunits, represents a promising target for the development of new drugs. We have previously demonstrated the feasibility of targeting the protein-protein interaction domain between the PB1 and PA subunits of the polymerase complex of influenza A virus using a small peptide derived from the PA-binding domain of PB1. However, this influenza A virus-derived peptide did not affect influenza B virus polymerase activity. Here we report that the PA-binding domain of the polymerase subunit PB1 of influenza A and B viruses is highly conserved and that mutual amino acid exchange shows that they cannot be functionally exchanged with each other. Based on phylogenetic analysis and a novel biochemical ELISA-based screening approach, we were able to identify an influenza A-derived peptide with a single influenza B-specific amino acid substitution which efficiently binds to PA of both virus types. This dual-binding peptide blocked the viral polymerase activity and growth of both virus types. Our findings provide proof of principle that protein-protein interaction inhibitors can be generated against influenza A and B viruses. Furthermore, this dual-binding peptide, combined with our novel screening method, is a promising platform to identify new antiviral lead compounds.

[1]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[2]  T. Tumpey,et al.  Resurrected pandemic influenza viruses. , 2009, Annual review of microbiology.

[3]  E. Obayashi,et al.  Structural insight into the essential PB1–PB2 subunit contact of the influenza virus RNA polymerase , 2009, The EMBO journal.

[4]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[5]  J. Carrascosa,et al.  The Structure of a Biologically Active Influenza Virus Ribonucleoprotein Complex , 2009, PLoS pathogens.

[6]  S. Cusack,et al.  The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit , 2009, Nature.

[7]  Zihe Rao,et al.  Crystal structure of an avian influenza polymerase PAN reveals an endonuclease active site , 2009, Nature.

[8]  L. Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[9]  M. Tomita,et al.  Design of peptide inhibitors for the importin alpha/beta nuclear import pathway by activity-based profiling. , 2008, Chemistry & biology.

[10]  T. Berg.  Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[11]  A. Joachimiak,et al.  Crystal structure of the polymerase PAC–PB1N complex from an avian influenza H5N1 virus , 2008, Nature.

[12]  E. Obayashi,et al.  The structural basis for an essential subunit interaction in influenza virus RNA polymerase , 2008, Nature.

[13]  Y. Kawaoka,et al.  Limited compatibility between the RNA polymerase components of influenza virus type A and B. , 2008, Virus research.

[14]  E. Holmes,et al.  The Evolutionary Dynamics of Human Influenza B Virus , 2008, Journal of Molecular Evolution.

[15]  Joe D. Lewis,et al.  The structural basis for cap binding by influenza virus polymerase subunit PB2 , 2008, Nature Structural &Molecular Biology.

[16]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[17]  T. Shinohara,et al.  [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[18]  S. Cusack,et al.  Three-dimensional model for the isolated recombinant influenza virus polymerase heterotrimer , 2007, Nucleic acids research.

[19]  Ronald Frank,et al.  Peptide-Mediated Interference with Influenza A Virus Polymerase , 2007, Journal of Virology.

[20]  Shibo Jiang,et al.  Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide , 2007, Cell.

[21]  M. Kiso,et al.  Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. , 2007, JAMA.

[22]  M. Kiso,et al.  Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.

[24]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[25]  Yoshihiro Kawaoka,et al.  The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. , 2005, Annual review of microbiology.

[26]  S. Dowell,et al.  A child with avian influenza A (H5N1) infection. , 2005, The Pediatric infectious disease journal.

[27]  D. Coen,et al.  Identification of a small molecule that inhibits herpes simplex virus DNA Polymerase subunit interactions and viral replication. , 2004, Chemistry & biology.

[28]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[29]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[30]  M. Schwemmle,et al.  Active Borna Disease Virus Polymerase Complex Requires a Distinct Nucleoprotein-to-Phosphoprotein Ratio but No Viral X Protein , 2003, Journal of Virology.

[31]  C. Yoakim,et al.  Inhibition of Human Papillomavirus DNA Replication by Small Molecule Antagonists of the E1-E2 Protein Interaction* , 2003, Journal of Biological Chemistry.

[32]  E. Fodor,et al.  Two Aromatic Residues in the PB2 Subunit of Influenza A RNA Polymerase Are Crucial for Cap Binding* , 2003, Journal of Biological Chemistry.

[33]  B. Yaspan,et al.  Inhibitors of cell migration that inhibit intracellular paxillin/alpha4 binding: a well-documented use of positional scanning libraries. , 2002, Chemistry & biology.

[34]  T. Deng,et al.  A Single Amino Acid Mutation in the PA Subunit of the Influenza Virus RNA Polymerase Inhibits Endonucleolytic Cleavage of Capped RNAs , 2002, Journal of Virology.

[35]  G. Brownlee,et al.  The RNA Polymerase of Influenza A Virus Is Stabilized by Interaction with Its Viral RNA Promoter , 2002, Journal of Virology.

[36]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Ruben O. Donis,et al.  Functional Analysis of PA Binding by Influenza A Virus PB1: Effects on Polymerase Activity and Viral Infectivity , 2001, Journal of Virology.

[38]  M. Schmidtke,et al.  A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. , 2001, Journal of virological methods.

[39]  R. Krug,et al.  The active sites of the influenza cap‐dependent endonuclease are on different polymerase subunits , 2001, The EMBO journal.

[40]  M. S. Taylor,et al.  Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. van der Werf,et al.  Comparative analysis of the ability of the polymerase complexes of influenza viruses type A, B and C to assemble into functional RNPs that allow expression and replication of heterotypic model RNA templates in vivo. , 1999, Virology.

[42]  R. Webster,et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.

[43]  A. Portela,et al.  The three subunits of the polymerase and the nucleoprotein of influenza B virus are the minimum set of viral proteins required for expression of a model RNA template. , 1997, Virology.

[44]  J. Ortín,et al.  The influenza A virus PB2 polymerase subunit is required for the replication of viral RNA , 1997, Journal of virology.

[45]  S. Pleschka,et al.  A plasmid-based reverse genetics system for influenza A virus , 1996, Journal of virology.

[46]  D. Pérez,et al.  A 48-amino-acid region of influenza A virus PB1 protein is sufficient for complex formation with PA , 1995, Journal of virology.

[47]  B. Schumacher,et al.  Vesicular stomatitis virus transcription inhibited by purified MxA protein. , 1995, Virology.

[48]  P. Palese,et al.  Infectious influenza A and B virus variants with long carboxyl terminal deletions in the NS1 polypeptides. , 1987, Virology.

[49]  S. Thacker,et al.  Morbidity and mortality associated with influenza B in the United States, 1979-1980. A report from the Center for Disease Control. , 1980, The Journal of infectious diseases.

[50]  P. Wright,et al.  Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. , 1980, The Journal of infectious diseases.

[51]  S. M. Martin,et al.  Severe illness with influenza B. , 1980, The American journal of medicine.

[52]  R. Chanock,et al.  Influenza A and B virus infection in infants and young children during the years 1957-1976. , 1979, American journal of epidemiology.

[53]  G. Noble,et al.  An influenza B epidemic within a remote Alaska community. Serologic, epidemiologic, and clinical observations. , 1970, JAMA.

[54]  M. Paulshock,et al.  Antiviral Activity of 1-Adamantanamine (Amantadine) , 1964, Science.